Drug slow release in osteomyelitis treatment is an important biomedical problem, to prepare the high effect drug sustained-release bead is the sticking point. A sustained-release bead system consisting of gentamicin sulfate in biodegradable poly(dimer acid-tetradecandioic acid) copolymer [P(DA-TA), WDA: WTA= 50: 50] is prepared by melt casting which may be useful in osteomyelitis treatment. The stability at room temperature and the in vitro release profile in distilling water, in 0.9% saline buffer and in 0.1 mol/LpH7.4 PBS at 37 degrees C of the bead are determined, the drug release behavior in vitro follows the first order release kinetics and Peppas release kinetics equation. In vitro bacteriostatic activity studies demonstrated that the beads possessed desired bacteriostatic activity and lasted for 50 days for Staphylococcus aureus and Escherichia coli, which are common bacteria for infections in bone. All the above suggest that the biodegradable sustained-release beads may be a new treatment device for osteomyelitis treatment.
Delayed-Action Preparations ; chemical synthesis ; pharmacology ; Dicarboxylic Acids ; administration & dosage ; chemical synthesis ; Drug Carriers ; Escherichia coli ; drug effects ; Gentamicins ; administration & dosage ; pharmacology ; Humans ; Microbial Sensitivity Tests ; Osteomyelitis ; drug therapy ; Polyanhydrides ; administration & dosage ; chemical synthesis ; Polymers ; administration & dosage ; chemical synthesis ; Staphylococcus aureus ; drug effects

OBJECTIVE: To explore the clinical signification of screening 16 target deafness mutations in GJB2, GJB3, SLC26A4, WFS1 and mitochondrial DNA 12S rRNA in 135 children patients with non-syndromic sensorineural hearing loss (NSHL) in Zibo City, Shandong province. METHOD: Peripheral blood samples of 135 subjects in the study diagnosed as NSHL were collected; Polymerase chain reaction (PCR) and direct sequencing were used to analyze the 16 mutation spots. RESULT: Sixty-two cases of 135 patients (45.9%, 62/135) were found out to be carries of at least one pathogenic gene mutation. Among them, 24 cases (17.8%, 24/135) had two mutated alleles (homozygote and compound heterozygote), and 38 cases (28.1%, 38/135) were single mutant carriers. Among all the children patients, 30 cases (22. 2%, 30/135) had SLC26A4 mutations, and 19 cases (14.1%, 19/135) had GJB2 mutations. In the study 86 Mutant alleles were detected, and the allele frequency of SLC26A4 c. 766_2A > G and GJB2 c. 235delC was 11.11% (30/270) and 8.5% (23/270) respectively. The allele frequency of SLC26A4 c. 2168A > G and WFS1 c. 2158A > G is 2.6% (7/270). CONCLUSION SLC26A4 mutation is the primary cause of the patients with NSHL in this study, and GJB2 mutation is the secondary. The most common mutant form is c. 766_2A of SLC26A4, and the second is c. 235delC of GJB2. GJB3 and WFS1 mutations were detected, whereas mtDNA mutations were not found out in this study.
Alleles ; Child ; Connexins ; DNA Mutational Analysis ; DNA, Mitochondrial ; Deafness ; Gene Frequency ; Hearing Loss ; Hearing Loss, Sensorineural ; genetics ; Heterozygote ; Homozygote ; Humans ; Mitochondria ; Mutation ; Polymerase Chain Reaction ; RNA, Ribosomal